Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance

Jaime P. Almandoz; Ildiko Lingvay; Javier Morales; Carlos Campos

doi:10.2337/cd19-0100

Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance

Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, Carlos Campos

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	390-402
Number of pages	13
Journal	Clinical Diabetes
Volume	38
Issue number	4
DOIs	https://doi.org/10.2337/cd19-0100
State	Published - Oct 1 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.2337/cd19-0100

Cite this

@article{fd4f68676cb6478e90f7625ef3553e33,

title = "Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance",

author = "Almandoz, {Jaime P.} and Ildiko Lingvay and Javier Morales and Carlos Campos",

note = "Funding Information: I.L. received research funding and/or consulting fees, travel, or editorial support from AstraZeneca, Boehringer Ingelheim, Intarcia,Janssen,Lilly,Mannkind,Merck,Mylan,Novo Nordisk, Novartis, Pfizer, Sanofi, and Valeritas. J.M. is on the speakers{\textquoteright} bureaus of and has served as a consultant for, received honoraria as a promotional speaker from, or participated in advisory boards for Abbott Laboratories, AstraZeneca, Bayer Laboratories, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Mylan Pharmaceuticals, and Novo Nordisk. C.C. is a speaker/consultant for Boehringer Ingelheim, Janssen, Lilly, Mannkind, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported. Funding Information: The development of and medical writing and editorial support for this article was funded by Novo Nordisk.",

year = "2020",

month = oct,

day = "1",

doi = "10.2337/cd19-0100",

language = "English (US)",

volume = "38",

pages = "390--402",

journal = "Clinical Diabetes",

issn = "0891-8929",

publisher = "American Diabetes Association Inc.",

number = "4",

}

TY - JOUR

T1 - Switching between glucagon-like peptide-1 receptor agonists

T2 - Rationale and practical guidance

AU - Almandoz, Jaime P.

AU - Lingvay, Ildiko

AU - Morales, Javier

AU - Campos, Carlos

N1 - Funding Information: I.L. received research funding and/or consulting fees, travel, or editorial support from AstraZeneca, Boehringer Ingelheim, Intarcia,Janssen,Lilly,Mannkind,Merck,Mylan,Novo Nordisk, Novartis, Pfizer, Sanofi, and Valeritas. J.M. is on the speakers’ bureaus of and has served as a consultant for, received honoraria as a promotional speaker from, or participated in advisory boards for Abbott Laboratories, AstraZeneca, Bayer Laboratories, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Mylan Pharmaceuticals, and Novo Nordisk. C.C. is a speaker/consultant for Boehringer Ingelheim, Janssen, Lilly, Mannkind, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported. Funding Information: The development of and medical writing and editorial support for this article was funded by Novo Nordisk.

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85097015735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097015735&partnerID=8YFLogxK

U2 - 10.2337/cd19-0100

DO - 10.2337/cd19-0100

M3 - Article

C2 - 33132510

AN - SCOPUS:85097015735

SN - 0891-8929

VL - 38

SP - 390

EP - 402

JO - Clinical Diabetes

JF - Clinical Diabetes

IS - 4

ER -

Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this